SEC Form 4 · accession 0001628280-26-042280
Acumen Pharmaceuticals, Inc. · ABOS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nathan B Fountain
Director
Period of report
Jun 9, 2026
Accepted (ET)
Jun 10, 2026 · 4:51 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001576885
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 9, 2026 | S | 6,400 | $2.2301 | D | 48,150 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $2.2300 to $2.2311. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.